Dendritic cell targeted vaccines: Recent progresses and challenges

References

• Ueno H, Klechevsky E, Schmitt N, Ni L, Flamar AL, Zurawski S, Zurawski G, Palucka K, Banchereau J, Oh S. Targeting human dendritic cell subsets for improved vaccines. Semin Immunol 2011; 23:21-7; PMID:21277223; http://dx.doi.org/10.1016/j.smim.2011.01.004
   PubMed Web of Science ®Google Scholar
• Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YT, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767; PMID:10837075; http://dx.doi.org/10.1146/annurev.immunol.18.1.767
   PubMed Web of Science ®Google Scholar
• Garcia-Vallejo JJ, van Kooyk Y. The physiological role of DC-SIGN: A tale of mice and men. Trends Immunol 2013; 34:482-6; PMID:23608151; http://dx.doi.org/10.1016/j.it.2013.03.001
   PubMed Web of Science ®Google Scholar
• Caminschi I, Shortman K. Boosting antibody responses by targeting antigens to dendritic cells. Trends Immunol 2012; 33:71-7; PMID:22153931; http://dx.doi.org/10.1016/j.it.2011.10.007
   PubMed Web of Science ®Google Scholar
• Inaba K, Inaba M, Naito M, Steinman RM. Dendritic cell progenitors phagocytose particulates, including bacillus Calmette-Guerin organisms, and sensitize mice to mycobacterial antigens in vivo. The Journal of experimental medicine 1993; 178:479-88; PMID:7688024; http://dx.doi.org/10.1084/jem.178.2.479
   PubMed Web of Science ®Google Scholar
• Moll H, Fuchs H, Blank C, Rollinghoff M. Langerhans cells transport Leishmania major from the infected skin to the draining lymph node for presentation to antigen-specific T cells. European journal of immunology 1993; 23:1595-601; PMID:8325337; http://dx.doi.org/10.1002/eji.1830230730
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C, Stahl PD, Austyn JM. Phagocytosis of antigens by Langerhans cells in vitro. The Journal of experimental medicine 1993; 178:509-19; PMID:8393477; http://dx.doi.org/10.1084/jem.178.2.509
   PubMed Web of Science ®Google Scholar
• Svensson M, Stockinger B, Wick MJ. Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells. J Immunol 1997; 158:4229-36; PMID:9126984
   PubMed Web of Science ®Google Scholar
• Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility Complex Class-Ii Compartment - down-Regulation by Cytokines and Bacterial Products. Journal of Experimental Medicine 1995; 182:389-400; PMID:7629501; http://dx.doi.org/10.1084/jem.182.2.389
   PubMed Web of Science ®Google Scholar
• Jiang WP, Swiggard WJ, Heufler C, Peng M, Mirza A, Steinman RM, Nussenzweig MC. The Receptor Dec-205 Expressed by Dendritic Cells and Thymic Epithelial-Cells Is Involved in Antigen-Processing. Nature 1995; 375:151-5; PMID:7753172; http://dx.doi.org/10.1038/375151a0
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. The Journal of experimental medicine 1994; 179:1109-18; PMID:8145033; http://dx.doi.org/10.1084/jem.179.4.1109
   PubMed Web of Science ®Google Scholar
• Yuseff MI, Pierobon P, Reversat A, Lennon-Dumenil AM. How B cells capture, process and present antigens: a crucial role for cell polarity. Nat Rev Immunol 2013; 13:475-86; PMID:23797063; http://dx.doi.org/10.1038/nri3469
   PubMed Web of Science ®Google Scholar
• Khan WN, Wright JA, Kleiman E, Boucher JC, Castro I, Clark ES, et al. B-lymphocyte tolerance and effector function in immunity and autoimmunity. Immunol Res 2013; 57:335-53; PMID:24293007; http://dx.doi.org/10.1007/s12026-013-8466-z
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A. Antigen-specific interaction between T and B cells. J Immunol 2007; 179:7206-8; PMID:18025160
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, George A, Bal V, Ravindran A, Rath S. Bruton's tyrosine kinase deficiency in macrophages inhibits nitric oxide generation leading to enhancement of IL-12 induction. J Immunol 1999; 163:1786-92; PMID:10438910
   PubMed Web of Science ®Google Scholar
• Martin F, Kearney JF. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol 2001; 13(2):13195-201
   Web of Science ®Google Scholar
• de Vinuesa CG, Cook MC, Ball J, Drew M, Sunners Y, Cascalho M, Wabl M, Klaus GG, MacLennan IC. Germinal centers without T cells. J Exp Med 2000; 191:485-93; PMID:10662794; http://dx.doi.org/10.1084/jem.191.3.485
   PubMed Web of Science ®Google Scholar
• van Zelm MC, van der Burg M, van Dongen JJM. Homeostatic and maturation-associated proliferation in the peripheral B-cell compartment. Cell Cycle 2007; 6:2890-5; PMID:18156800; http://dx.doi.org/10.4161/cc.6.23.4952
   PubMed Web of Science ®Google Scholar
• Unger WWJ, van Beelen AJ, Bruijns SC, Joshi M, Fehres CM, van Bloois L, Verstege MI, Ambrosini M, Kalay H, Nazmi K, et al. Glycan-modified liposomes boost CD4(+) and CD8(+) T-cell responses by targeting DC-SIGN on dendritic cells. J Control Release 2012; 160:88-95; PMID:22366522; http://dx.doi.org/10.1016/j.jconrel.2012.02.007
   PubMed Web of Science ®Google Scholar
• Kastenmuller W, Kastenmuller K, Kurts C, Seder RA. Dendritic cell-targeted vaccines - hope or hype? Nat Rev Immunol 2014; 14:705-11; PMID:25190285; http://dx.doi.org/10.1038/nri3727
   PubMed Web of Science ®Google Scholar
• Shortman K, Lahoud MH, Caminschi I. Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med 2009; 41:61-6; PMID:19287186; http://dx.doi.org/10.3858/emm.2009.41.2.008
   PubMed Web of Science ®Google Scholar
• De Souza JB. Protective immunity against malaria after vaccination. Parasite Immunol 2014;36:131-9; PMID:24188045; http://dx.doi.org/10.1111/pim.12086
   PubMed Web of Science ®Google Scholar
• Andersen P, Woodworth JS; Tuberculosis vaccines - rethinking the current paradigm. Trends Immunol 2014; 35:387-95; PMID:24875637; http://dx.doi.org/10.1016/j.it.2014.04.006
   PubMed Web of Science ®Google Scholar
• Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20:621-67; PMID:11861614; http://dx.doi.org/10.1146/annurev.immunol.20.100301.064828
   PubMed Web of Science ®Google Scholar
• Palucka K, Ueno H, Fay J, Banchereau J. Harnessing Dendritic Cells to Generate Cancer Vaccines. Ann Ny Acad Sci 2009; 1174:88-98; PMID:19769741; http://dx.doi.org/10.1111/j.1749-6632.2009.05000.x
   PubMed Web of Science ®Google Scholar
• Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15:138-47; PMID:12633662; http://dx.doi.org/10.1016/S0952-7915(03)00015-3
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, Oh S, Fay J, Pascual V, Banchereau J, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010; 234:199-212; PMID:20193020; http://dx.doi.org/10.1111/j.0105-2896.2009.00884.x
   PubMed Web of Science ®Google Scholar
• Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007; 26:503-17; PMID:17398124; http://dx.doi.org/10.1016/j.immuni.2007.03.006
   PubMed Web of Science ®Google Scholar
• Draube A, Klein-Gonzalez N, Mattheus S, Brillant C, Hellmich M, Engert A, von Bergwelt-Baildon M. Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-Analysis. Plos One 2011; 6:e18801; PMID:21533099; http://dx.doi.org/10.1371/journal.pone.0018801
   PubMed Web of Science ®Google Scholar
• Lesterhuis WJ, de Vries IJM, Schreibelt G, Lambeck AJA, Aarntzen EHJG, Jacobs JFM, Scharenborg NM, van de Rakt MW, de Boer AJ, Croockewit S, et al. Route of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma Patients. Clin Cancer Res 2011; 17:5725-35; PMID:21771874; http://dx.doi.org/10.1158/1078-0432.CCR-11-1261
   PubMed Web of Science ®Google Scholar
• Den Dunnen J, Gringhuis SI, Geijtenbeek TBH. Innate signaling by the C-type lectin DC-SIGN dictates immune responses. Cancer Immunol Immun 2009; 58:1149-57; http://dx.doi.org/10.1007/s00262-008-0615-1
   PubMed Web of Science ®Google Scholar
• Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature 2006; 440:808-12; PMID:16489357; http://dx.doi.org/10.1038/nature04596
   PubMed Web of Science ®Google Scholar
• Sporri R, Sousa CRE. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4(+) T cell populations lacking helper function. Nature Immunology 2005; 6:163-70; PMID:15654341; http://dx.doi.org/10.1038/ni1162
   PubMed Web of Science ®Google Scholar
• Tighe H, Takabayashi K, Schwartz D, Marsden R, Beck L, Corbeil J, Richman DD, Eiden JJ Jr, Spiegelberg HL, Raz E. Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol 2000; 30:1939-47; PMID:10940883; http://dx.doi.org/10.1002/1521-4141(200007)30:7%3c1939::AID-IMMU1939%3e3.0.CO;2-
   PubMed Web of Science ®Google Scholar
• Tighe H, Takabayashi K, Schwartz D, Van Nest G, Tuck S, Eiden JJ, Kagey-Sobotka A, Creticos PS, Lichtenstein LM, Spiegelberg HL, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immun 2000; 106:124-34; PMID:10887315; http://dx.doi.org/10.1067/mai.2000.107927
   PubMed Web of Science ®Google Scholar
• Horner AA, Datta SK, Takabayashi K, Belyakov IM, Hayashi T, Cinman N, Nguyen MD, Van Uden JH, Berzofsky JA, Richman DD, et al. Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites. J Immunol 2001; 167:1584-91; PMID:11466380; http://dx.doi.org/10.4049/jimmunol.167.3.1584
   PubMed Web of Science ®Google Scholar
• Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, Song L, Nakaar V, Powell TJ. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007; 25:763-75; PMID:16968658; http://dx.doi.org/10.1016/j.vaccine.2006.08.013
   PubMed Web of Science ®Google Scholar
• Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8(+) T cell tolerance. J Exp Med 2002; 196:1627-38; PMID:12486105; http://dx.doi.org/10.1084/jem.20021598
   PubMed Web of Science ®Google Scholar
• Moris A, Nobile C, Buseyne F, Porrot F, Abastado JP, Schwartz O, et al. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. Blood 2004; 103:2648-54; PMID:14576049; http://dx.doi.org/10.1182/blood-2003-07-2532
   PubMed Web of Science ®Google Scholar
• Tacken PJ, de Vries IJM, Gijzen K, Joosten B, Wu DY, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106:1278-85; PMID:15878980; http://dx.doi.org/10.1182/blood-2005-01-0318
   PubMed Web of Science ®Google Scholar
• Basu S, Binder RJ, Ramalingam T, Srivastava PK. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 2001; 14:303-13; PMID:11290339; http://dx.doi.org/10.1016/S1074-7613(01)00111-X
   PubMed Web of Science ®Google Scholar
• Heit A, Gebhardt F, Lahl K, Neuenhahn M, Schmitz F, Anderl F, Wagner H, Sparwasser T, Busch DH, Kastenmüller K. Circumvention of regulatory CD4(+) T cell activity during cross-priming strongly enhances T cell-mediated immunity. Eur J Immunol 2008; 38:1585-97; PMID:18465771; http://dx.doi.org/10.1002/eji.200737966
   PubMed Web of Science ®Google Scholar
• Cho HJ, Takabayashi K, Cheng PM, Nguyen MD, Corr M, Tuck S, Raz E. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol 2000; 18:509-14; PMID:10802617; http://dx.doi.org/10.1038/75365
   PubMed Web of Science ®Google Scholar
• Kastenmuller K, Wille-Reece U, Lindsay RWB, Trager LR, Darrah PA, Flynn BJ, Becker MR, Udey MC, Clausen BE, Igyarto BZ, et al. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J Clin Invest 2011; 121:1782-96; PMID:21540549; http://dx.doi.org/10.1172/JCI45416
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Flynn BJ, Lore K, Koup RA, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA. HIV Gag protein conjugated to a toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8(+) T cell responses in nonhuman primates. Proc Natl Acad Sci USA 2005; 102:15190-4; PMID:16219698; http://dx.doi.org/10.1073/pnas.0507484102
   PubMed Web of Science ®Google Scholar
• Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8(+) T cell responses. J Immunol 2005; 174:7676-83; PMID:15944268; http://dx.doi.org/10.4049/jimmunol.174.12.7676
   PubMed Web of Science ®Google Scholar
• Szeles L, Meissner F, Dunand-Sauthier I, Thelemann C, Hersch M, Singovski S, Haller S, Gobet F, Fuertes Marraco SA, Mann M, et al. TLR3-Mediated CD8+ Dendritic Cell Activation Is Coupled with Establishment of a Cell-Intrinsic Antiviral State. J Immunol 2015; 195(3):1025-33; PMID:26101320
   PubMed Web of Science ®Google Scholar
• Jackson DC, Lau YF, Le T, Suhrbier A, Deliyannis G, Cheers C, Smith C, Zeng W, Brown LE. A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses. Proc Natl Acad Sci USA 2004; 101:15440-5; PMID:15489266; http://dx.doi.org/10.1073/pnas.0406740101
   PubMed Web of Science ®Google Scholar
• Wang BL, Henao-Tamayo M, Harton M, Ordway D, Shanley C, Basaraba RJ, Orme IM. A toll-like receptor-2-directed fusion protein vaccine against tuberculosis. Clin Vaccine Immunol 2007; 14:902-6; PMID:17616633; http://dx.doi.org/10.1128/CDLI.00077-07
   PubMed Web of Science ®Google Scholar
• Singh SK, Stephani J, Schaefer M, Kalay H, Garcia-Vallejo JJ, den Haan J, Saeland E, Sparwasser T, van Kooyk Y. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation. Mol Immunol 2009; 47:164-74; PMID:19818504; http://dx.doi.org/10.1016/j.molimm.2009.09.026
   PubMed Web of Science ®Google Scholar
• Chen HJ, Yuan BQ, Zheng ZC, Liu Z, Wang SS. Lewis X oligosaccharides-heparanase complex targeting to DCs enhance antitumor response in mice. Cell Immunol 2011; 269:144-8; PMID:21570677; http://dx.doi.org/10.1016/j.cellimm.2011.03.021
   PubMed Web of Science ®Google Scholar
• Garcia-Vallejo JJ, Ambrosini M, Overbeek A, van Riel WE, Bloem K, Unger WWJ, Chiodo F, Bolscher JG, Nazmi K, Kalay H, et al. Multivalent glycopeptide dendrimers for the targeted delivery of antigens to dendritic cells. Mol Immunol 2013; 53:387-97; PMID:23103377; http://dx.doi.org/10.1016/j.molimm.2012.09.012
   PubMedGoogle Scholar
• Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 2012; 33:4229-39; PMID:22410170; http://dx.doi.org/10.1016/j.biomaterials.2012.02.036
   PubMed Web of Science ®Google Scholar
• Singh SK, Streng-Ouwehand I, Litjens M, Kalay H, Burgdorf S, Saeland E, Kurts C, Unger WW, van Kooyk Y. Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization. Eur J Immunol 2011; 41:916-25; PMID:21400496; http://dx.doi.org/10.1002/eji.201040762
   PubMed Web of Science ®Google Scholar
• Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8(+) T cells. Nat Immunol 2005; 6:593-9; PMID:15864309; http://dx.doi.org/10.1038/ni1201
   PubMed Web of Science ®Google Scholar
• Trumpfheller C, Finke JS, Lopez CB, Moran TM, Moltedo B, Soares H, Huang Y, Schlesinger SJ, Park CG, Nussenzweig MC, et al. Intensified and protective CD4(+) T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med 2006; 203:607-17; PMID:16505141; http://dx.doi.org/10.1084/jem.20052005
   PubMed Web of Science ®Google Scholar
• Boscardin SB, Hafalla JCR, Masilamani RF, Kamphorst AO, Zebroski HA, Rai U, Morrot A, Zavala F, Steinman RM, Nussenzweig RS, et al. Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses. J Exp Med 2006; 203:599-606; PMID:16505139; http://dx.doi.org/10.1084/jem.20051639
   PubMed Web of Science ®Google Scholar
• Lahoud MH, Ahmet F, Kitsoulis S, Wan SS, Vremec D, Lee CN, Phipson B, Shi W, Smyth GK, Lew AM, et al. Targeting Antigen to Mouse Dendritic Cells via Clec9A Induces Potent CD4 T Cell Responses Biased toward a Follicular Helper Phenotype. J Immunol 2011; 187:842-50; PMID:21677141; http://dx.doi.org/10.4049/jimmunol.1101176
   PubMed Web of Science ®Google Scholar
• Corbett AJ, Caminschi I, McKenzie BS, Brady JL, Wright MD, Mottram PL, Hogarth PM, Hodder AN, Zhan Y, Tarlinton DM, et al. Antigen delivery via two molecules on the CD8(−) dendritic cell subset induces humoral immunity in the absence of conventional “danger”. Eur J Immunol 2005; 35:2815-25; PMID:16143986; http://dx.doi.org/10.1002/eji.200526100
   PubMed Web of Science ®Google Scholar
• Sancho D, Joffre OP, Keller AM, Rogers NC, Martinez D, Hernanz-Falcon P, Rosewell I, Reis e Sousa C. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009; 458:899-903; PMID:19219027; http://dx.doi.org/10.1038/nature07750
   PubMed Web of Science ®Google Scholar
• Caminschi I, Ahmet F, Heger K, Brady J, Nutt SL, Vremec D, Pietersz S, Lahoud MH, Schofield L, Hansen DS, et al. Putative IKDCs are functionally and developmentally similar to natural killer cells, but not to dendritic cells. J Exp Med 2007; 204:2579-90; PMID:17923506; http://dx.doi.org/10.1084/jem.20071351
   PubMed Web of Science ®Google Scholar
• Beyer M, Wang HW, Peters N, Doths S, Koerner-Rettberg C, Openshaw PJ, Schwarze J. The beta2 integrin CDIIc distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Resp Res 2005; 6:70; http://dx.doi.org/10.1186/1465-9921-6-70
   PubMed Web of Science ®Google Scholar
• Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier LL, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006; 12:207-13; PMID:16444266; http://dx.doi.org/10.1038/nm1352
   PubMed Web of Science ®Google Scholar
• Wang H, Griffiths MN, Burton DR, Ghazal P. Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization. Proc Natl Acad Sci USA 2000; 97:847-52; PMID:10639168; http://dx.doi.org/10.1073/pnas.97.2.847
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Torensma R, Figdor CG. Targeting antigens to dendritic cells in vivo. Immunobiology 2006; 211:599-608; PMID:16920498; http://dx.doi.org/10.1016/j.imbio.2006.05.021
   PubMed Web of Science ®Google Scholar
• Bolland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 1999; 72:149-77; PMID:10361574; http://dx.doi.org/10.1016/S0065-2776(08)60019-X
   PubMed Web of Science ®Google Scholar
• Wallace PK, Tsang KY, Goldstein J, Correale P, Jarry TM, Schlom J, Guyre PM, Ernstoff MS, Fanger MW. Exogenous antigen targeted to Fc gamma RI on myeloid cells is presented in association with MHC class I. J Immunol Methods 2001; 248:183-94; PMID:11223078; http://dx.doi.org/10.1016/S0022-1759(00)00351-3
   PubMed Web of Science ®Google Scholar
• Flacher V, Tripp CH, Haid B, Kissenpfennig A, Malissen B, Stoitzner P, Idoyaga J, Romani N. Skin Langerin(+) Dendritic Cells Transport Intradermally Injected Anti-DEC-205 Antibodies but Are Not Essential for Subsequent Cytotoxic CD8(+) T Cell Responses. J Immunol 2012; 188:2146-55; PMID:22291181; http://dx.doi.org/10.4049/jimmunol.1004120
   PubMed Web of Science ®Google Scholar
• Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, Carrington M, Nussenzweig MC, Piperno AG, Steinman RM. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8(+) T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci USA 2007; 104:1289-94; PMID:17229838; http://dx.doi.org/10.1073/pnas.0610383104
   PubMed Web of Science ®Google Scholar
• Njongmeta LM, Bray J, Davies CJ, Davis WC, Howard CJ, Hope JC, Palmer GH, Brown WC, Mwangi W. CD205 antigen targeting combined with dendritic cell recruitment factors and antigen-linked CD40L activation primes and expands significant antigen-specific antibody and CD4(+) T cell responses following DNA vaccination of outbred animals. Vaccine 2012; 30:1624-35; PMID:22240344; http://dx.doi.org/10.1016/j.vaccine.2011.12.110
   PubMed Web of Science ®Google Scholar
• Ramakrishna V, Treml JF, Vitale L, Connolly JE, O'Neill T, Smith PA, Jones CL, He LZ, Goldstein J, Wallace PK, et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules. J Immunol 2004; 172:2845-52; PMID:14978085; http://dx.doi.org/10.4049/jimmunol.172.5.2845
   PubMed Web of Science ®Google Scholar
• Caminschi I, Vremec D, Ahmet F, Lahoud MH, Villadangos JA, Murphy KM, Heath WR, Shortman K. Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3(−/−) mice. Mol Immunol 2012; 50:9-17; PMID:22209163; http://dx.doi.org/10.1016/j.molimm.2011.11.008
   PubMed Web of Science ®Google Scholar
• Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, Carlyle JR, Reis e Sousa C. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 2008; 118:2098-110; PMID:18497879; http://dx.doi.org/10.1172/JCI34584
   PubMed Web of Science ®Google Scholar
• Castro FVV, Tutt AL, White AL, Teeling JL, James S, French RR, Glennie MJ. CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur J Immunol 2008; 38:2263-73; PMID:18651710; http://dx.doi.org/10.1002/eji.200838302
   PubMed Web of Science ®Google Scholar
• Regnault A, Lankar D, Lacabanne V, Rodriguez A, Thery C, Rescigno M, Saito T, Verbeek S, Bonnerot C, Ricciardi-Castagnoli P, et al. Fc gamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189:371-80; PMID:9892619; http://dx.doi.org/10.1084/jem.189.2.371
   PubMed Web of Science ®Google Scholar
• Flinsenberg TWH, Compeer EB, Koning D, Klein M, Amelung FJ, van Baarle D, Boelens JJ, Boes M. Fc gamma receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3(+) dendritic cells. Blood 2012; 120:5163-72; PMID:23093620; http://dx.doi.org/10.1182/blood-2012-06-434498
   PubMed Web of Science ®Google Scholar
• Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Mi 2013; 3:13
   PubMed Web of Science ®Google Scholar
• Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, Lambeck AJ, Figdor CG. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011; 118:6836-44; PMID:21967977; http://dx.doi.org/10.1182/blood-2011-07-367615
   PubMed Web of Science ®Google Scholar
• Hamdy S, Haddadi A, Shayeganpour A, Samuel J, Lavasanifar A. Activation of Antigen-Specific T Cell-Responses by Mannan-Decorated PLGA Nanoparticles. Pharm Res-Dordr 2011; 28:2288-01; http://dx.doi.org/10.1007/s11095-011-0459-9
   PubMed Web of Science ®Google Scholar
• Schreibelt G, Klinkenberg LJJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, Adema GJ, Brown GD, Figdor CG, de Vries IJ. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3(+) myeloid dendritic cells. Blood 2012; 119:2284-92; PMID:22234694; http://dx.doi.org/10.1182/blood-2011-08-373944
   PubMed Web of Science ®Google Scholar
• Thomann JS, Heurtault B, Weidner S, Braye M, Beyrath J, Fournel S, Schuber F, Frisch B. Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting. Biomaterials 2011; 32:4574-83; PMID:21474175; http://dx.doi.org/10.1016/j.biomaterials.2011.03.015
   PubMed Web of Science ®Google Scholar
• Yang L, Yang H, Rideout K, Cho T, Il Joo K, Ziegler L, Elliot A, Walls A, Yu D, Baltimore D, et al. Engineered lentivector targeting of dendritic cells for in vivo immunization. Nat Biotechnol 2008; 26:326-34; PMID:18297056; http://dx.doi.org/10.1038/nbt1390
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Fokkink R, Joosten B, Stuart MC, Albericio F, Torensma R, Figdor CG. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 2010; 144:118-26; PMID:20156497; http://dx.doi.org/10.1016/j.jconrel.2010.02.013
   PubMed Web of Science ®Google Scholar
• Arigita C, Bevaart L, Everse LA, Koning GA, Hennink WE, Crommelin DJA, van de Winkel JG, van Vugt MJ, Kersten GF, Jiskoot W. Liposomal meningococcal B vaccination: Role of dendritic cell targeting in the development of a protective immune response. Infect Immun 2003; 71:5210-8; PMID:12933866; http://dx.doi.org/10.1128/IAI.71.9.5210-5218.2003
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Rueda F, Cordobilla B, Simon L, Hosta L, Albericio F, Domingo JC. Targeting Nanosystems to Human DCs via Fc Receptor as an Effective Strategy to Deliver Antigen for Immunotherapy. Mol Pharmaceut 2011; 8:104-16; http://dx.doi.org/10.1021/mp100178k
   PubMed Web of Science ®Google Scholar
• Hangalapura BN, Oosterhoff D, de Groot J, Boon L, Tuting T, van den Eertwegh AJ, Gerritsen WR, van Beusechem VW, Pereboev A, Curiel DT, et al. Potent Antitumor Immunity Generated by a CD40-Targeted Adenoviral Vaccine. Cancer Res 2011; 71:5827-37; PMID:21747119; http://dx.doi.org/10.1158/0008-5472.CAN-11-0804
   PubMed Web of Science ®Google Scholar
• Brandao JG, Scheper RJ, Lougheed SM, Curiel DT, Tillman BW, Gerritsen WR, van den Eertwegh AJ, Pinedo HM, Haisma HJ, de Gruijl TD. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 2003; 21:2268-72; PMID:12744857; http://dx.doi.org/10.1016/S0264-410X(03)00050-1
   PubMed Web of Science ®Google Scholar